USD 12.03
(4.66%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 1.31 Billion USD | 31.11% |
2022 | 1 Billion USD | 9.62% |
2021 | 915 Million USD | 0.22% |
2020 | 913 Million USD | -14.75% |
2019 | 1.07 Billion USD | 7.75% |
2018 | 994 Million USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | 1.26 Billion USD | -3.95% |
2024 Q3 | 1.38 Million USD | 7.46% |
2024 Q2 | 1.28 Billion USD | 1.9% |
2023 Q1 | 1.12 Billion USD | 11.76% |
2023 FY | 1.31 Billion USD | 31.11% |
2023 Q4 | 1.31 Billion USD | 10.88% |
2023 Q3 | 1.18 Billion USD | -1.08% |
2023 Q2 | 1.19 Billion USD | 6.96% |
2022 Q3 | 879 Million USD | -7.47% |
2022 Q2 | 950 Million USD | 0.42% |
2022 Q1 | 946 Million USD | 3.39% |
2022 FY | 1 Billion USD | 9.62% |
2022 Q4 | 1 Billion USD | 14.11% |
2021 Q3 | 918 Million USD | 5.4% |
2021 Q2 | 871 Million USD | -5.74% |
2021 FY | 915 Million USD | 0.22% |
2021 Q1 | 924 Million USD | 1.2% |
2021 Q4 | 915 Million USD | -0.33% |
2020 Q4 | 913 Million USD | 0.0% |
2020 FY | 913 Million USD | -14.75% |
2020 Q1 | - USD | 0.0% |
2019 FY | 1.07 Billion USD | 7.75% |
2018 FY | 994 Million USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
AbbVie Inc. | 4.09 Billion USD | 67.919% |
Bristol-Myers Squibb Company | 2.66 Billion USD | 50.601% |
Bristol-Myers Squibb Company Ce | 2.66 Billion USD | 50.601% |
Johnson & Johnson | 11.18 Billion USD | 88.239% |
Eli Lilly and Company | 5.77 Billion USD | 77.221% |
Merck & Co., Inc. | 6.35 Billion USD | 79.317% |
Novartis AG | 5.91 Billion USD | 77.761% |
Pfizer Inc. | 10.18 Billion USD | 87.094% |